Opana’s a goner.

When the FDA claims your product is associated with outbreaks of:

  • HIV
  • Hep C
  • Thrombotic Microangiopathy…


…what do you get? You get your walking papers.


In June, the FDA asked Endo Pharmaceuticals to remove reformulated Opana ER from the marketplace. According to their press release, the FDA claims Opana ER is subject to dangerous abuse and manipulation through injections. This is the first time they have successfully removed a currently-marketed opioid pain medication due to public health issues.


Although, as you might expect, Big Pharma continues to tout the safety and efficacy of this product. In contrast, the FDA is claiming the product’s risks outweigh its benefits.


In related news, President Trump just declared a national public health emergency to combat the opioid epidemic. This means Federal dollars will be available to help states deal with addiction.


#ByeFelicia. It’s past time to do better.


Call us. We can do better.

William Faris, JD
Chief Executive Officer

Posted in Bill's Favorite Files, Medical Cost Containment, OMCA